Healthcare professionals Careers Media About us Contact us Search Search Home What we do Our medicines Community Partnerships Inside ViiV Healthcare We research and develop new HIV medicines We are focused on finding new medicines to improve outcomes for people living with HIV and understanding how best to prevent and treat the disease. We are focused on finding new medicines to improve outcomes for people living with HIV and understanding how best to prevent and treat the disease. At ViiV Healthcare our scientists are 100% dedicated to finding new ways to limit the impact of HIV on the 35 million people living with the virus. Although there have been significant advances in HIV therapy in recent years, until we have a cure we must maintain investment into developing new medicines and remain vigilant over how the virus evolves resistance to treatment. We know that new medicines will always be needed that are at least as effective as current options and treat patients who have limited options due to the development of resistance. Additionally, new medicines will need to offer improvements in areas such as tolerability, safety, dosing schedules, drug interactions and convenience. As well as the five investigational medicines we currently have in the clinic, our investment in R&D supports early work to identify new therapeutic options such as antiretroviral drug candidates with novel mechanisms of action and treatment of HIV-related immune dysfunction. We actively collaborate with other commercial and academic organisations to work towards a cure and also seek new business alliances to ensure we will deliver the innovative HIV treatments of the future. Find out more about how we collaborate to innovate. Another avenue of research that we have prioritised is the investigation of innovative strategies and uses of existing antiretroviral agents. Examples include investigating our medicines in preventing HIV infection as Pre-Exposure Prophylaxis (PreP) and Treatment as Prevention (TasP). We have also begun a study of long-acting preparations (LAP) which could potentially reduce dosing frequency from daily pills to monthly or quarterly injections. The development of paediatric formulations is also a high priority for ViiV Healthcare such as our collaboration with CHAI & Mylan on a low-cost dispersible medicine for children living with HIV in developing countries. Read more We also recognise that in spite of many scientific advances there are still too many gaps in our understanding of how best to prevent and treat HIV in certain populations and areas of the world. That’s why we are currently supporting 36 collaborative research studies to address public health priority areas among 38,000 adults and children living with HIV in resource-limited settings. Prioritising research into HIV in children In order to expand the research evidence base in children, 24 of the 36 collaborative research trials we currently support in the developing world are investigating prevention of mother-to-child HIV transmission and paediatric treatment strategies. In addition our £10 million Paediatric Innovation Seed Fund supports diverse research initiatives in Asia, Africa and Eastern Europe to improve the diagnosis, treatment and care of infants and children living with HIV. Find out more about the Paediatric Innovation Seed Fund. What we do We research and develop new HIV medicines We improve access to our medicines We partner with the HIV community We collaborate to innovate US Patient Assistance Programmes Dolutegravir Expanded Access Program Related articles Medicines in development HIV in children Improving diagnosis & treatment of infants in Africa ©2015 ViiV Healthcare. Accessibility Privacy policy Terms of use Terms and conditions Connect with us